The FY2025 results show a revenue decline and a massive reported loss from litigation, but the core business excluding that provision was stable. The FY2026 guidance of declining Core Operating Profit and Core EPS reflects heavy investment in three near-term launches. The key swing factor is regulatory and commercial execution on oveporexton, rusfertide, and zasocitinib — success could drive a re-rating, while delays or failures would leave the company with a declining mature portfolio and no new growth engine. Monitor FDA decisions and launch trajectories over the next 12 months.
Price Chart
Executive Summary
Takeda filed its 2026 Annual Integrated Report (FY2025, ended March 31, 2026) via Form 6-K. Core Revenue declined 2.6% at CER to ¥4,505.7B ($28.3B), driven by VYVANSE loss of exclusivity, partially offset by Growth & Launch Products (+4.5% CER). Core Operating Profit fell 0.9% at CER to ¥1,172.5B. Reported Operating Profit plunged 98.2% due to a provision for AMITIZA antitrust litigation. Reported EPS was -¥97. The company guides FY2026 Core Revenue to decline low-single-digit % CER and Core Operating Profit to decline 5-8% CER, with substantial launch investments. The pipeline is the key catalyst: three assets (oveporexton, rusfertide, zasocitinib) poised for launch within 12 months, with FDA Priority Review for two.
Key Facts
- FY2025 Core Revenue ¥4,505.7B ($28.3B), -2.6% CER YoY
- Core Operating Profit ¥1,172.5B ($7.4B), -0.9% CER YoY
- Reported Operating Profit ¥6.2B, -98.2% YoY due to AMITIZA antitrust provision
- Reported EPS -¥97; Core EPS ¥517 (+5.2% YoY)
- FY2026 guidance: Core Revenue low-single-digit % decline CER; Core Operating Profit -5% to -8% CER
- FY2026 Core EPS guided to mid-teens % decline CER; dividend raised to ¥204/share
- Three pipeline assets (oveporexton, rusfertide, zasocitinib) expected to launch within 12 months
- FDA granted Priority Review for oveporexton and rusfertide
- Adjusted Net Debt/Adjusted EBITDA at 2.6x; target 2x
- Transformation Program targeting >¥200B annualized savings by FY2028, ~¥100B in FY2026
Financial Impact
FY2025 Core Revenue declined ¥74.1B (-1.6% AER, -2.6% CER) to ¥4,505.7B. Core Operating Profit declined ¥9.8B (-0.9% CER) to ¥1,172.5B. Reported Operating Profit fell ¥336.4B (-98.2% AER) due to AMITIZA provision. Core EPS ¥517 vs ¥491 prior year. FY2026 guidance implies Core Revenue of ¥4,640B (+3.0% reported) but low-single-digit % decline CER; Core Operating Profit ¥1,160B (-1.1% reported, -5% to -8% CER).
Risk Factors
- AMITIZA antitrust litigation: provision already taken, but post-trial motions and appeal ongoing; further adverse outcomes could add liability
- FY2026 Core Operating Profit guided down 5-8% CER; Core EPS mid-teens % decline — earnings headwind from launch investment and tax rate normalization
- Pipeline execution risk: oveporexton, rusfertide, zasocitinib launches may underperform or face regulatory delays
- Leverage at 2.6x Adjusted Net Debt/EBITDA, above 2x target; deleveraging pace depends on cash flow and launch success
- VYVANSE loss of exclusivity continues to pressure revenue; mature portfolio headwinds expected in FY2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001395064-26-000185 |
| Document: form6k-3_062426.htm | 0001395064-26-000185 |
| Document: 0001395064-26-000185-index-headers.html | 0001395064-26-000185 |
| Document: 0001395064-26-000185-index.html | 0001395064-26-000185 |
| Document: 0001395064-26-000185.txt | 0001395064-26-000185 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $18.60 $18.89 | ▲ +1.56% | ▲ +1.45% | $17.86 (−3.98%) |
Aug 21, 2026 6w ago | Insider Cluster | $18.18 $18.03 | ▼ −0.83% | ▼ −1.30% | $17.86 (−1.76%) |
Aug 19, 2026 6w ago | Insider Cluster | $18.34 $18.23 | ▼ −0.60% | ▼ −0.21% | $17.86 (−2.62%) |
Aug 14, 2026 7w ago | Court Ruling | $17.63 $18.18 | ▲ +3.12% | ▲ +4.49% | $17.86 (+1.30%) |
Aug 13, 2026 7w ago | Insider Cluster | $17.39 $18.13 | ▲ +4.26% | ▲ +6.22% | $17.86 (+2.70%) |
Aug 13, 2026 7w ago | Insider Cluster | $17.39 $18.13 | ▲ +4.26% | ▲ +6.22% | $17.86 (+2.70%) |
Jul 9, 2026 12w ago | 6-K | $16.61 $16.73 | ▲ +0.72% | ▲ +0.85% | $17.86 (+7.53%) |
Jul 8, 2026 12w ago | 6-K | $16.75 $16.39 | ▼ −2.15% | ▼ −3.01% | $17.86 (+6.63%) |
Jul 6, 2026 12w ago | 3 | $16.89 $16.56 | ▼ −1.95% | ▼ −2.44% | $17.86 (+5.74%) |
Jun 29, 2026 13w ago | 6-K | $15.98 $16.89 | ▲ +5.69% | ▲ +4.31% | $17.86 (+11.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access